CTXR - Rasio rega marang prakiraan pendapatan Citius Pharmaceuticals Inc.

Citius Pharmaceuticals (CTXR) faces a fierce patent battle in the critical care sector, where trial failures are critical. Meanwhile, operating within the US legal framework eliminates sanction risks. The forward P/S ratio, with a value fixed at 2.10, helps assess market valuation relative to expected sales. Citius Pharmaceuticals is pursuing the expansion of Lymphir oncology drugs to capture the hospital segment.

Citius Pharma - Prakiraan rega marang pendapatan CTXR (periode 14.02.2026 - 13.11.2026)

Rincian metrik komprehensif lan analitis citiuspharma.com (CTXR)

- rega pasar lan target rega analis:

Bagan rega Citius Pharmaceuticals, Inc.|CTXR - Bagan rega target

- statistik kapitalisasi pasar:

Nilai pasar Citius Pharmaceuticals, Inc.|CTXR - Total Nilai Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham Citius Pharmaceuticals|CTXR - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih citiuspharma.com|CTXR - Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas Citius Pharmaceuticals|CTXR - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Citius Pharmaceuticals, Inc.|CTXR - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Citius Pharmaceuticals, Inc.|CTXR - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Citius Pharmaceuticals|Likuiditas cepet citiuspharma.com

- rincian asil keuangan lan kelipatan valuasi:

CTXR - Bathi pungkasan|Proyeksi bathi mangsa ngarep Citius Pharmaceuticals|CTXR - Pangali P/E|Rega marang bathi mangsa ngarep Citius Pharmaceuticals, Inc.|CTXR - Rasio kapitalisasi marang bathi lan wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Citius Pharmaceuticals, Inc.|CTXR - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Citius Pharmaceuticals|CTXR - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan citiuspharma.com|CTXR - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Citius Pharmaceuticals

- data pendapatan lan penerimaan dodolan:

CTXR - Total dodolan perusahaan|Prakiraan volume dodolan Citius Pharmaceuticals, Inc.|CTXR - Koefisien rega marang pendapatan|Multiplikator forward rega marang pendapatan Citius Pharmaceuticals, Inc.

Analisis umum perusahaan:Citius Pharma CTXR

Produk sing diprodhuksi Citius Pharmaceuticals Inc.

An investment audit of Citius Pharmaceuticals (CTXR) requires an analysis of the ratio between current market capitalization and projected revenue, which allows for an assessment of the value of each unit of future sales. For a biotech company with a narrow oncology portfolio, the expected P/S metric becomes a critical indicator reflecting the degree of market optimism priced in regarding the successful commercialization of drugs and the risks associated with dependence on clinical trial outcomes.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte INCY|Hutchison MediPharma - Rasio rega marang prakiraan pendapatan|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One Biopharmaceuticals Inc|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan inhibrx.com INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharma FENC|Multiplikator forward rega marang pendapatan HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Rega forward marang dodolan|Coherus Biosciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRBP (corbuspharma.com)|Cardiff Oncology Corp - Multiplikator Forward P/S|Rega forward marang dodolan BYSI (BeyondSpring, Inc.)|BCAB: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Lixte Biotechnology, Inc. (LIXT)|Rasio rega marang prakiraan pendapatan Cellectar Biosciences|BLRX: Rega forward marang dodolan|Multiplikator Forward P/S CANF|Multiplikator Forward P/S aprea.com (APRE)|Rasio rega marang prakiraan pendapatan Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep chimerix.com|CYCC: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan G1 Therapeutics|KRON (Kronos Bio Corp) - Multiplikator Forward P/S|Kintara Pharma (KTRA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan ONCT (Oncternal Therapeutics)|Rasio rega marang pendapatan sing dikarepake PRTG